CCTG

About CCTG

The California Collaborative Treatment Group (CCTG) is a clinical trials consortium of academic institutions and community-based organizations in Southern California.

Since 1986, the CCTG has conducted high-impact, multi-center, investigator-initiated clinical trials focusing on:

HIV treatment and management
Risk reduction behavioral interventions
Pre-Exposure Prophylaxis (PrEP)
The CCTG research team includes clinicians, psychologists, behavioral scientists, biostatisticians, and pharmacology experts.

Collaborators

The CCTG Administrative Core is located at the UCSD AVRC. Collaborators include:

University of Southern California (USC) 5P21 Rand Schrader Clinic in Los Angeles
LA Biomedical Research Institute at Harbor-UCLA in Torrance
Long Beach Department of Health and Human Services (DHHS) in Long Beach
Los Angeles LGBT Center in West Hollywood
Family Health Centers of San Diego in San Diego

Current Studies

Current funding for the CCTG is provided by the California HIV/AIDS Research Program (CHRP) and backed by the California State Legislature. CHRP fosters outstanding and innovative research that responds to the needs of all people of California, especially those who are often underserved, by accelerating progress in prevention, education, care, treatment, and a cure for HIV/AIDS.

Participate in a Study

Community members interested in participating in a study should contact the Screening Coordinator:

Screening Coordinator
(619) 543-8080

Recent Publications & Results

Study	Authors	Publication/ Conference	Title
CCTG 600	Jill Blumenthal, MD et al	International Workshop on HIV & Women	PrEPing for a PrEP Demonstration Project: Understanding Awareness and Perspectives among Women in Southern California
CCTG 596	Kathleen Jacobson, MD et al	National HIV Prevention Conference	Best Practices for Incentivized Social Network Recruitment for HIV Case Finding
CCTG 595	Martin Hoenigl, MD et al	2017 Conference on Retroviruses and Opportunistic Infections	Substance-using MSM on HIV Pre-Exposure Prophylaxis Have Better Adherence
CCTG 595	Michael Dubé, MD et al	18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV	Tenofovir disoproxil fumarate associated with Fanconi syndrome in an HIV uninfected man receiving HIV pre-exposure prophylaxis
CCTG 595	David Moore, PhD et al	HIV Research for Prevention	Randomized Controlled Trial of Daily Text Messages for Adherence to Pre-Exposure Prophylaxis (PrEP) in Men who have Sex with Men and Transgender Women
CCTG 595	Jill Blumenthal, MD et al	International AIDS Society	Text messaging responses correlate with tenofovir-disphosphate dried blood spot concentrations among men who have sex with men on pre-exposure prophylaxis
CCTG 595	Joel Milam, PhD et al	International AIDS Society	Risk compensation among men who have sex with men (MSM) in Southern California following the initiation of pre-exposure prophylaxis (PrEP)
CCTG 595	Sheldon Morris, MD MPH et al	National Summit HCV and HIV Diagnosis, Prevention, and Access to Care	Comparison of behavioral factors in men who have sex with men who go on HIV pre-exposure prophylaxis by partner status
595	Eric Ellorin, et al	Infectious Diseases Society of America	Barriers to Health Insurance Coverage and Intention to Continue Pre-Exposure Prophylaxis (PrEP) Reported by Men who have Sex with Men (MSM) in a PrEP Demonstration Project
CCTG 593	Katya Corado, MD et al	National HIV Prevention Conference	Can We Improve HIV Prevention Services?: Understanding the Rationale for Expressed Lack of Interest in PrEP in Recently HIV-tested Individuals
CCTG 592	Sara Gianella, MD et al	BMC Infectious Diseases	Genital Epstein Barr Virus is associated with Higher Prevalence and Persistence of Anal Human Papilloma Virus in HIV-Infected Men on Antiretroviral Therapy
CCTG 590	Nadejda Beliakova-Bethell, PhD et al	Antiviral Research	Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression
CCTG 589	Maile Karris, MD et al	HIV Clinical Trials	HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen
CCTG 589	Maile Karris, MD et al	Journal of Acquired Immune Deficiency Syndromes	Nucleoside-sparing Regimens with Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue